Trulieve Announces Exclusive Partnership with DeLisioso Cannabis in Florida

Flamingo Kush by DeLisioso pre-rolls available exclusively at Trulieve beginning April 15

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States today announced an exclusive partnership in Florida with DeLisioso LLC ("DeLisioso"), a cannabis marketing and consulting company specializing in high-end adult use and medical cannabis products. Through the agreement, Trulieve becomes the exclusive producer, processor and retailer of DeLisioso branded products throughout the state, with Flamingo Kush by DeLisioso pre-rolls launching on April 15 .

DeLisioso is a Florida -based cannabis brand founded by Richard DeLisi and his son Rick. Richard DeLisi is one of the longest-serving nonviolent cannabis prisoner in United States history having served 32 years of a 90-year sentence. The DeLisioso brand is committed to donating a portion of its profits to nonprofits including www.FreeDeLisi.com and The Last Prisoner Project, an organization that was instrumental in securing DeLisi's release in December 2020 .

"We're thrilled to add the DeLisioso brand to our selection of high-quality medical products throughout Florida ," said Kim Rivers , Chief Executive Officer of Trulieve. "Richard's personal story of injustice and how he uses his platform to benefit others is an inspiration. Couple that with the brand's premium flower and it excites us to bring these products to patients in the communities we serve in Florida ."

Available at all of Trulieve's Florida dispensaries upon launch, Flamingo Kush by DeLisioso pre-rolls is an indica-dominant strain with minty, spicy, and lemony tones. Flamingo Kush, which is a Kush Mints variant phenotype cultivated with Trulieve genetics, will also be available in whole flower offerings in the weeks following the initial product launch.

"It's a dream come true to announce our partnership with Trulieve and bring the DeLisioso brand to cannabis connoisseurs in my home state," said Richard DeLisi . "After serving over 32 years in jail for a nonviolent cannabis conviction, this agreement marks a monumental and full circle moment for myself and DeLisioso to be able to legally sell cannabis. Our purpose is not only to provide exceptional cannabis products but to also aid families around the world who have been affected by the War on Drugs with each of our sales. We are grateful for Trulieve's support since they are Florida's largest cannabis company and share a similar mission to bring cannabis for all."

As the leading medical cannabis provider in Florida , Trulieve offers the largest selection of THC and CBD products in a variety of delivery methods, including edibles, smokable flower, concentrates, tinctures, topical creams, vaporizers, and more. Trulieve also offers statewide home delivery, convenient online ordering, and in-store pickup.

About DeLisioso
DeLisioso LLC is a cannabis marketing & consulting company founded by Richard DeLisi and his son, Rick DeLisi . DeLisioso specializes in high-end recreational and medicinal cannabis products available to consumers and patients globally. DeLisioso products are from exclusive cultivators and are sought after by cannabis connoisseurs worldwide. The brand's success is used to contribute resources required to free nonviolent cannabis prisoners across the globe. Richard was one of the longest-serving nonviolent cannabis prisoners in United States history, serving 32 years. The war on drugs impacted the DeLisi family and continues to impact millions of families across the globe. The DeLisioso brand shines a much-needed light on the family members affected by the incarceration of their loved ones. For more information, please visit https://DeLisioso.com or https://freedelisi.com .

Instagram: @_DeLisioso_

Media Contact
Ken Darby , Chief Revenue Officer
+1 (407) 733-6550
Ken@DeLisioso.net

About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S. operating in 11 states, with leading market positions in Arizona , Florida , and Pennsylvania . Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com .

Facebook: @Trulieve
Instagram: @Trulieve_
Twitter: @Trulieve

Investor Contact
Christine Hersey , Executive Director of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com

Media Contact
Rob Kremer , Executive Director of Corporate Communications
+1 (404) 218-3077
Robert.Kremer@Trulieve.com

MATTIO Communications
Trulieve@Mattio.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/trulieve-announces-exclusive-partnership-with-delisioso-cannabis-in-florida-301516316.html

SOURCE Trulieve Cannabis Corp.

Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/April2022/04/c7713.html

News Provided by Canada Newswire via QuoteMedia

TCNNF,TRUL:CNX
The Conversation (0)
Cannabis plant.

What Would US Cannabis Rescheduling Mean for Stocks and Investors?

The US Drug Enforcement Administration (DEA) has initiated proceedings to reclassify cannabis from a Schedule I substance to a Schedule III substance, marking a significant step towards cannabis reform in the country.

After months of deliberation, the Associated Press reported on April 30 that the DEA would move to reclassify cannabis from Schedule I, a category it currently shares with heroin and methamphetamines, to Schedule III, which is reserved for substances with low potential for dependence and accepted medical use.

The move from the DEA comes almost a year after the Department of Health and Human Services (HHS) suggested that cannabis be reclassified on August 29, 2023. In December 2023, the DEA sent a letter to Congress in which it indicated its intent to review the evidence provided by the HHS. This was followed by months of evaluation and consideration by the DEA, as well as discussions and advocacy for cannabis reform by lawmakers and other stakeholders.

Keep reading...Show less
Cannabis leaves, US flag.

Cannabis Round-Up: US Moves to Reschedule Cannabis, Tilray Brands Seeks US Acquisitions

May saw officials in the Drug Enforcement Administration make the first moves toward cannabis rescheduling.

As anticipation builds, companies are beginning to better position themselves for changing market dynamics, and one Canadian cannabis company is anticipating major acquisition deals to come out of the US.

Meanwhile, a major player in the US market narrowly avoided consequences related to their Nasdaq listing after an expected merger agreement was terminated, and a once luxury cannabis brand out of California became officially delisted after months of financial uncertainty. Keep reading to discover more about these industry-shaping events.

Keep reading...Show less

Trulieve Announces Opening of 200th Dispensary

New Location in Brooksville, Florida opens today with grand opening celebration on June 14 th

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced the opening of a new medical cannabis dispensary in Brooksville, Florida marking the Company's 200 th dispensary in the United States .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve Announces Litigation Settlement and Acquisition of Ohio Assets

Trulieve adds two medical dispensaries in Beavercreek and Columbus to Ohio footprint

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced that it has reached an agreement resolving the active litigation.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Cronos Group Inc. to Speak at Bernstein's 40th Annual Strategic Decisions Conference

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company"), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President and CEO, will speak at Bernstein's 40th Annual Strategic Decisions Conference on Thursday, May 30, 2024, at 2:30PM ET.

A live webcast will be available on the Investors section of the Company's website at https://ir.thecronosgroup.com/events-presentations .

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Cronos Terminates Sale-Leaseback of Peace Naturals Campus

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company") announced today that it has terminated its agreement (the "Sale Agreement") with Future Farmco Canada Inc. (the "Buyer"), for the sale and leaseback of its property located at 4491 Concession 12 Sunnidale Road, Stayner, Ontario, Canada, L0M 1S0 (the "Peace Naturals Campus"). The Buyer did not satisfy or waive its due diligence and financing condition by the May 27, 2024 deadline, as set forth in the Sale Agreement. All amounts paid by the Buyer as part of a security deposit that were previously held in trust have been returned, in accordance with the Sale Agreement. The Company is continuing to evaluate its strategic options for the Peace Naturals Campus, which may include continuing and expanding operations at the facility.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×